195 related articles for article (PubMed ID: 21465190)
21. A Validation Study for Recurrence Risk Stratification of Stage II Colon Cancer Using the 55-Gene Classifier.
Shinto E; Oki E; Shimokawa M; Yamaguchi S; Ishiguro M; Morita M; Kusumoto T; Tomita N; Hashiguchi Y; Tanaka M; Ohnuma S; Tada S; Matsushima T; Hase K
Oncology; 2020; 98(8):534-541. PubMed ID: 32235113
[TBL] [Abstract][Full Text] [Related]
22. Development and independent validation of a prognostic assay for stage II colon cancer using formalin-fixed paraffin-embedded tissue.
Kennedy RD; Bylesjo M; Kerr P; Davison T; Black JM; Kay EW; Holt RJ; Proutski V; Ahdesmaki M; Farztdinov V; Goffard N; Hey P; McDyer F; Mulligan K; Mussen J; O'Brien E; Oliver G; Walker SM; Mulligan JM; Wilson C; Winter A; O'Donoghue D; Mulcahy H; O'Sullivan J; Sheahan K; Hyland J; Dhir R; Bathe OF; Winqvist O; Manne U; Shanmugam C; Ramaswamy S; Leon EJ; Smith WI; McDermott U; Wilson RH; Longley D; Marshall J; Cummins R; Sargent DJ; Johnston PG; Harkin DP
J Clin Oncol; 2011 Dec; 29(35):4620-6. PubMed ID: 22067406
[TBL] [Abstract][Full Text] [Related]
23. Prognosis of stage II colon cancer by non-neoplastic mucosa gene expression profiling.
Barrier A; Roser F; Boëlle PY; Franc B; Tse C; Brault D; Lacaine F; Houry S; Callard P; Penna C; Debuire B; Flahault A; Dudoit S; Lemoine A
Oncogene; 2007 Apr; 26(18):2642-8. PubMed ID: 17043639
[TBL] [Abstract][Full Text] [Related]
24. DNA mismatch repair status and colon cancer recurrence and survival in clinical trials of 5-fluorouracil-based adjuvant therapy.
Sinicrope FA; Foster NR; Thibodeau SN; Marsoni S; Monges G; Labianca R; Kim GP; Yothers G; Allegra C; Moore MJ; Gallinger S; Sargent DJ
J Natl Cancer Inst; 2011 Jun; 103(11):863-75. PubMed ID: 21597022
[TBL] [Abstract][Full Text] [Related]
25. Anticipating the clinical use of prognostic gene expression-based tests for colon cancer stage II and III: is Godot finally arriving?
Sveen A; Nesbakken A; Ågesen TH; Guren MG; Tveit KM; Skotheim RI; Lothe RA
Clin Cancer Res; 2013 Dec; 19(24):6669-77. PubMed ID: 24166914
[TBL] [Abstract][Full Text] [Related]
26. Girdin (GIV) Expression as a Prognostic Marker of Recurrence in Mismatch Repair-Proficient Stage II Colon Cancer.
Ghosh P; Tie J; Muranyi A; Singh S; Brunhoeber P; Leith K; Bowermaster R; Liao Z; Zhu Y; LaFleur B; Tran B; Desai J; Jones I; Croxford M; Jover R; Goel A; Waring P; Hu S; Teichgraber V; Rohr UP; Ridder R; Shanmugam K; Gibbs P
Clin Cancer Res; 2016 Jul; 22(14):3488-98. PubMed ID: 27029492
[TBL] [Abstract][Full Text] [Related]
27. Stage II colon cancer prognosis prediction by tumor gene expression profiling.
Barrier A; Boelle PY; Roser F; Gregg J; Tse C; Brault D; Lacaine F; Houry S; Huguier M; Franc B; Flahault A; Lemoine A; Dudoit S
J Clin Oncol; 2006 Oct; 24(29):4685-91. PubMed ID: 16966692
[TBL] [Abstract][Full Text] [Related]
28. A molecular signature for the prediction of recurrence in colorectal cancer.
Wang L; Shen X; Wang Z; Xiao X; Wei P; Wang Q; Ren F; Wang Y; Liu Z; Sheng W; Huang W; Zhou X; Du X
Mol Cancer; 2015 Feb; 14(1):22. PubMed ID: 25645394
[TBL] [Abstract][Full Text] [Related]
29. A TMEFF2-regulated cell cycle derived gene signature is prognostic of recurrence risk in prostate cancer.
Georgescu C; Corbin JM; Thibivilliers S; Webb ZD; Zhao YD; Koster J; Fung KM; Asch AS; Wren JD; Ruiz-Echevarría MJ
BMC Cancer; 2019 May; 19(1):423. PubMed ID: 31060542
[TBL] [Abstract][Full Text] [Related]
30. A 15-gene signature for prediction of colon cancer recurrence and prognosis based on SVM.
Xu G; Zhang M; Zhu H; Xu J
Gene; 2017 Mar; 604():33-40. PubMed ID: 27998790
[TBL] [Abstract][Full Text] [Related]
31. Tumor microRNA-29a expression and the risk of recurrence in stage II colon cancer.
Weissmann-Brenner A; Kushnir M; Lithwick Yanai G; Aharonov R; Gibori H; Purim O; Kundel Y; Morgenstern S; Halperin M; Niv Y; Brenner B
Int J Oncol; 2012 Jun; 40(6):2097-103. PubMed ID: 22426940
[TBL] [Abstract][Full Text] [Related]
32. Expression of apoptosis regulating proteins identifies stage II and III colon cancer patients with high risk of recurrence.
Belt EJ; Stockmann HB; Delis-van Diemen PM; Bril H; Tijssen M; van Essen HF; Heymans MW; Beliën JA; Carvalho B; Cillessen SA; Meijer GA
J Surg Oncol; 2014 Mar; 109(3):255-65. PubMed ID: 24249458
[TBL] [Abstract][Full Text] [Related]
33. A combined analysis of mismatch repair status and thymidylate synthase expression in stage II and III colon cancer.
Öhrling K; Karlberg M; Edler D; Hallström M; Ragnhammar P
Clin Colorectal Cancer; 2013 Jun; 12(2):128-35. PubMed ID: 23276521
[TBL] [Abstract][Full Text] [Related]
34. A gene signature of 8 genes could identify the risk of recurrence and progression in Dukes' B colon cancer patients.
Bandrés E; Malumbres R; Cubedo E; Honorato B; Zarate R; Labarga A; Gabisu U; Sola JJ; García-Foncillas J
Oncol Rep; 2007 May; 17(5):1089-94. PubMed ID: 17390049
[TBL] [Abstract][Full Text] [Related]
35. High microsatellite instability (MSI-H) is associated with distinct clinical and molecular characteristics and an improved survival in early Colon cancer (CC); real world data from the AIO molecular registry Colopredict Plus.
Noepel-Duennebacke S; Juette H; Feder IS; Kluxen L; Basara N; Hiller W; Herzog T; Klaassen-Mielke R; Mueller L; Senkal M; Engel L; Teschendorf C; Trenn G; Verdoodt B; Wolters H; Uhl W; Reinacher-Schick A; Tannapfel A
Z Gastroenterol; 2020 Jun; 58(6):533-541. PubMed ID: 32544965
[TBL] [Abstract][Full Text] [Related]
36. ColoGuideEx: a robust gene classifier specific for stage II colorectal cancer prognosis.
Agesen TH; Sveen A; Merok MA; Lind GE; Nesbakken A; Skotheim RI; Lothe RA
Gut; 2012 Nov; 61(11):1560-7. PubMed ID: 22213796
[TBL] [Abstract][Full Text] [Related]
37. Gene expression profiling of nonneoplastic mucosa may predict clinical outcome of colon cancer patients.
Barrier A; Boelle PY; Lemoine A; Tse C; Brault D; Chiappini F; Lacaine F; Houry S; Huguier M; Flahault A; Dudoit S
Dis Colon Rectum; 2005 Dec; 48(12):2238-48. PubMed ID: 16228831
[TBL] [Abstract][Full Text] [Related]
38. Lumican and versican are associated with good outcome in stage II and III colon cancer.
de Wit M; Belt EJ; Delis-van Diemen PM; Carvalho B; Coupé VM; Stockmann HB; Bril H; Beliën JA; Fijneman RJ; Meijer GA
Ann Surg Oncol; 2013 Dec; 20 Suppl 3(Suppl 3):S348-59. PubMed ID: 22711178
[TBL] [Abstract][Full Text] [Related]
39. Ubiquitin D is an independent prognostic marker for survival in stage IIB-IIC colon cancer patients treated with 5-fluoruracil-based adjuvant chemotherapy.
Zhao S; Jiang T; Tang H; Cui F; Liu C; Guo F; Lu H; Xue Y; Jiang W; Peng Z; Yan D
J Gastroenterol Hepatol; 2015 Apr; 30(4):680-8. PubMed ID: 25238407
[TBL] [Abstract][Full Text] [Related]
40. Stromal VCAN expression as a potential prognostic biomarker for disease recurrence in stage II-III colon cancer.
Chida S; Okayama H; Noda M; Saito K; Nakajima T; Aoto K; Hayase S; Momma T; Ohki S; Kono K; Takenoshita S
Carcinogenesis; 2016 Sep; 37(9):878-887. PubMed ID: 27287872
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
